Enzymatica AB: Enzymatica signs distribution agreement with Endeavour Consumer Health

Regulatory information

Enzymatica has partnered with Endeavour Consumer Health, a division of Symbion which is a member of EBOS Group. The agreement grants Endeavour Consumer Health exclusive rights to sell, market and distribute ColdZyme® in Australia and New Zealand. It is Enzymatica's first agreement outside the European Union (EU) and a breakthrough in the company's strategic initiative to further establish ColdZyme in the international market.

The agreement covers the products ColdZyme 20ml and ColdZyme OneCold 7ml.

The regulatory requirements for medical devices in Australia differ from those in the EU, meaning ColdZyme will be registered in a higher class of medical devices. The registration process is expected to take 12-18 months and the launch is planned for 2018, ready for the cold & flu season in Australia.

"The agreement with Endeavour Consumer Health is an important breakthrough in our strategic international expansion outside Europe, and Endeavour Consumer Health is the perfect partner for us. They are well established and have significant experience launching new products to the market, which will favour the introduction of ColdZyme in Australia and New Zealand", said Fredrik Lindberg, CEO of Enzymatica.


EBOS Group's General Manager - Retail Services, Andrew Vidler, said ColdZyme would complement Endeavour Consumer Health's existing product offering.

"We are very excited about the agreement with Enzymatica to sell ColdZyme in Australia. ColdZyme is different to traditional cold therapies and fits well into our business model to grow our business in the over the counter (OTC) health products market with innovative new products."

For more information, please contact:

Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com

This information is information that Enzymatica AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16.00 CET on November 2, 2016.

About Enzymatica
Enzymatica AB is a Life sciences company that develops and sells medical devices for fighting infectious diseases. In a short period of time, the company developed ColdZyme®, a unique mouth spray for fighting colds, launched the product in seven markets and established it as one of the bestselling cold products in Swedish pharmacies measured in SEK. Our strategy is to continue growing by strengthening our position on existing markets and expanding to more geographic markets via established partners. The company's head office is in Lund and it is listed on the Nasdaq First North. For more information, please go to: www.enzymatica.se.

Enzymaticas Certified Adviser is Erik Penser Bankaktiebolag.

About Endeavour Consumer Health
Endeavour Consumer Health is a trans-Tasman business dedicated to providing its retail partners and their customers with affordable, high-quality health and personal care products.

The business was formed in 2014 from the amalgamation of Symbion Consumer Products in Australia and the consumer division of EBOS Healthcare in New Zealand and Australia.

Endeavour Consumer Health is part of Symbion, a member of EBOS Group Ltd.  EBOS Group is the largest and most diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products.

For more information visit www.ebosgroup.com

Enzymatica cares about your privacy and processes your personal data in accordance with the EU’s General Data Protection Regulation. For more information about how we handle your personal information, and what rights you have, please refer to our personal data processing document here.